Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Recruiting

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Correlation With AKR1C3 Enzyme Expression of AST-001 in Subjects With Advanced Solid Tumors

Outcome
Ongoing
Phase
Phase 1 / Phase 2
Status
Recruiting
Study type
Interventional
Start
7 July 2022
Expected end
31 August 2027
Enrollment
180 participants
Sites
1
Primary outcomes
Incidence and severity of adverse events (AEs); Assess safety changes in electrocardiogram (ECG); Assess safety changes of body weight.; Number of participants with dose limiting toxicities (DLTs); Define the Recommended Phase 2 Dose (RP2D)
Sponsor type
Industry
Results posted
No
Last update
7 February 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.